Replies to post #429775 on Amarin Corp Plc (AMRN)

[Number sleven]

Study, I think some of you guys are confusing the difference between an FDA approved indication and patent infringement. The generic companies have an indication for SHTG. This was granted by FDA. Amarin no longer has patent protection for that indication. Thank you Nevada. We still have patent protection for the CVD indication. FDA isn't the patent Police. The courts are. Generic companies are selling a product considered to be an equivalent to Vascepa. (For the approved indication). The system substitutes that product for any and all indications. This is the basis of the legal controversy. The patent holder can not be held liable for infringement. I don't understand the confusion.
The financial value of Amarin releasing an authorized generic is a different debate.
Sleven,